5-Bromo-2-Chlorobenzoic Acid CAS 21739-92-4 Dapagliflozin Intermediate Assay ≥99.0% (HPLC)
Manufacturer Supply, High Purity, Commercial Production
Dapagliflozin (CAS: 461432-26-8) Related Intermediates:
5-Bromo-2-Chlorobenzoic Acid CAS 21739-92-4
5-Bromo-2-Chloro-4'-Ethoxydiphenylmethane CAS 461432-23-5
2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone CAS 32384-65-9
| Chemical Name | 5-Bromo-2-Chlorobenzoic Acid |
| Synonyms | 2-Chloro-5-Bromobenzoic Acid; 5-Bromo-2-Chlorobenzoate; BCBA |
| CAS Number | 21739-92-4 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C7H4BrClO2 |
| Molecular Weight | 235.46 |
| Melting Point | 157.0 to 160.0℃ (lit.) |
| COA & MSDS | Available |
| Place of Origin | Shanghai, China |
| Brand | Ruifu Chemical |
| Item | Specifications | Results |
| Appearance | Off-White to Light Yellow Powder | Conforms |
| Assay / Analysis Method | ≥99.0% (HPLC) | 99.65% |
| Melting Point | 157.0~160.0℃ | Conforms |
| Water (K.F) | ≤0.50% | 0.13% |
| 2-Chlorobenzoic Acid | ≤0.30% | <0.30% |
| 2-Chloro-3-Bromobenzoic Acid | ≤0.30% | <0.30% |
| Total Impurities | ≤1.00% | 0.35% |
| Infrared Spectrum | Conforms to Structure | Conforms |
| 1H NMR Spectrum | Conforms to Structure | Conforms |
| Conclusion | The product has been tested and complies with the given specifications | |
| Application | Intermediate of Dapagliflozin (CAS: 461432-26-8), type II diabetes | |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.
Hazard Symbols Xi - Irritant
Risk Codes
36/37/38 - Irritating to eyes, respiratory system and skin.
Safety Description
S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S37/39 - Wear suitable gloves and eye/face protection
WGK Germany 3
HS Code 2916399090
Hazard Class IRRITANT
5-Bromo-2-Chlorobenzoic Acid (CAS: 21739-92-4) is used as a starting material in the synthesis of Dapagliflozin (CAS: 461432-26-8), a selective sodium-glucose cotransporter-2 inhibitor that reduces renal glucose reabsorption and is used to treat patients with type II diabetes. Dapagliflozin is a potent and selective SGLT-2(SLC5A2 )inhibitor with EC50 of 1.1 nM. It has good permeability across Caco-2 cell membranes and is a substrate for P-glycoprotein (P-gp). Dapagliflozin was approved in 2012 by FDA.
